RARRES2 and graft versus host disease: Although the validation of this result in a larger cohort of patients is required, this evidence further supports the involvement of chemerin in the early immune-mediating events occurring after HSCT and suggests this protein as a potential predictive biomarker to guide patient-specific preemptive therapy to avoid GvHD onset and improve HSCT outcome (65–67).